ARCH Venture Management, LLC — 13F Holdings & Portfolio
CIK 1274403 · latest 13F-HR filed 2026-08-14
ARCH Venture Management, LLC manages $1.10B in 13F-reported U.S. long-equity assets across 12 reported positions as of its 2026-06-30 13F-HR filing. Its largest disclosed positions are PBLS (15.95%), BEAM (14.16%), RAPP (14.12%). Quarter over quarter (versus its 2026-03-31 filing) the fund opened 3 new positions and exited 1; 6 existing positions rose in reported value and 2 fell.
AUM is the long-equity portion reported on Form 13F-HR. Excludes short positions, cash, foreign holdings, and non-13F assets. For informational purposes only — not investment advice.
Long-equity book
Distinct positions
Filed 2026-08-14
vs 2026-03-31
Portfolio charts
Latest quarter's book, what changed, and how the portfolio has evolved across filings.
| Name | Title / Status | Ownership | Type |
|---|
Quarter-over-quarter changes
Changes in reported position value vs the prior 13F, so price moves count too, not just shares bought or sold.
Top Adds (vs prior quarter)
- BEAM THERAPEUTICS INC$47.6M +44.0%
- RAPPORT THERAPEUTICS INC$38.7M +33.2%
- ERASCA INC$15.2M +13.2%
- VIR BIOTECHNOLOGY INC$13.6M +11.8%
- GENERATE BIOMEDICINES INC$8.5M +35.0%
New Positions
- PARABILIS MEDICINES INC$175.5M
- SEAPORT THERAPEUTICS INC$136.6M
- BOUNDLESS BIO INC$6.7M
ARCH Venture Management, LLC Holdings (2026-06-30)
Rows tagged Call or Put are options positions, not stock. Per SEC Form 13F-HR, Value shows the notional value of the underlying (shares covered × underlying price), not the option premium. Shares is the number of underlying shares covered (divide by 100 for contract count).
| # | Issuer | Symbol | CUSIP | Value | Weight | Shares | Type |
|---|---|---|---|---|---|---|---|
| 1 | PARABILIS MEDICINES INC | PBLS | 698955101 | $175.5M | 15.95% | 6,412,780 | SH |
| 2 | BEAM THERAPEUTICS INC | BEAM | 07373V105 | $155.8M | 14.16% | 4,540,132 | SH |
| 3 | RAPPORT THERAPEUTICS INC | RAPP | 75383L102 | $155.4M | 14.12% | 3,728,738 | SH |
| 4 | SEAPORT THERAPEUTICS INC | SPTX | 81221K108 | $136.6M | 12.42% | 6,294,951 | SH |
| 5 | ERASCA INC | ERAS | 29479A108 | $129.9M | 11.81% | 7,091,557 | SH |
| 6 | VIR BIOTECHNOLOGY INC | VIR | 92764N102 | $129.4M | 11.76% | 12,694,163 | SH |
| 7 | MAZE THERAPEUTICS INC | MAZE | 578784100 | $123.0M | 11.18% | 4,120,053 | SH |
| 8 | LYELL IMMUNOPHARMA INC | LYEL | 55083R203 | $45.5M | 4.14% | 3,247,162 | SH |
| 9 | GENERATE BIOMEDICINES INC | GENB | 370920100 | $32.8M | 2.98% | 1,944,426 | SH |
| 10 | 10X GENOMICS INC | TXG | 88025U109 | $8.4M | 0.76% | 217,834 | SH |
| 11 | BOUNDLESS BIO INC | BOLD | 10170A100 | $6.7M | 0.61% | 2,694,095 | SH |
| 12 | GOSSAMER BIO INC | GOSS | 38341P102 | $1.3M | 0.12% | 8,055,916 | SH |
| Period | Filed | AUM | Holdings | Accession |
|---|---|---|---|---|
| 2026-06-30 | 2026-08-14 | $1.10B | 12 | 0001012975-26-000794 |
| 2026-03-31 | 2026-05-15 | $677.1M | 10 | 0001012975-26-000461 |
| 2025-12-31 | 2026-02-17 | $651.7M | 9 | 0001012975-26-000153 |
| 2025-09-30 | 2025-11-14 | $492.4M | 9 | 0001012975-25-000787 |
8755 W. HIGGINS RD. #1025
CHICAGO, IL 60631